Open at the publisher →
In force since 2024-03-20, as the publisher states.
Copy read on 2026-11-10. The page it was read from
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.
sha256 00ae5867ae91c55282784f8df9b28b7b31b4f5d96d3ffaea9b78a8243de081ec
3 provisions
Title and introductory text
2024 No. 190
Dangerous Drugs
The Misuse of Drugs Act 1971 (Amendment) Order 2024
Made
21st February 2024
Coming into force
20th March 2024
At the Court at Buckingham Palace, the 21st day of February 2024
Present,
The King’s Most Excellent Majesty in Council
In accordance with section 2(5) of the Misuse of Drugs Act 1971, a draft of this Order has been laid before Parliament after consultation with the Advisory Council on the Misuse of Drugs and approved by a resolution of each House of Parliament.
Accordingly, His Majesty, in exercise of the powers conferred on Him by section 2(2) of that Act, is pleased, by and with the advice of His Privy Council, to order, and it is hereby ordered, as follows:
Propose a change1 Citation, commencement and extent
(1) This Order may be cited as the Misuse of Drugs Act 1971 (Amendment) Order 2024 and comes into force on the twenty-eighth day after the day on which it is made.
(2) This Order extends to England and Wales, Scotland and Northern Ireland.
Propose a change2 Amendments to the Misuse of Drugs Act 1971
(1) The following amendments are made to Schedule 2 to the Misuse of Drugs Act 1971.
(2) In Part 1 (which specifies the drugs which are subject to control as Class A drugs) in paragraph 1(a)—
(a) after “Bezitramide.” insert “Brorphine.”;
(b) after “Bufotenine.” insert “Butonitazene.”;
(c) after “Ecgonine, and any derivate of ecgonine which is convertible to ecgonine or to cocaine.” insert “Ethyleneoxynitazene.”;
(d) after “Eticyclidine.” insert “Etodesnitazene (etazene).”;
(e) after “Fentanyl.” insert “Flunitazene.”;
(f) after “Isomethadone.” insert “Isotonitazene.”;
(g) after “Methyldihydromorphine (6-methyldihydromorphine).” insert—
Metodesnitazene (metazene).
Metonitazene.
;
(h) after “Properidine (1-methyl-4-phenyl-piperdine-4-carboxylic acid isopropyl ester).” insert “Protonitazene.”;
(i) after “1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45).” insert—
N-Desethyl etonitazene.
N-Desethylisotonitazene.
N-Desethyl protonitazene.
;
(j) after “4-Phenylpiperidine-4-carboxylic acid ethyl ester.” insert—
N-Piperidinyl-etonitazene (etonitazepipne).
N-Pyrrolidino-etonitazene (etonitazepyne).
N-Pyrrolidino protonitazene.
.
(3) In Part 2 (which specifies the drugs which are subject to control as Class B drugs) in paragraph 1(a)—
(a) after “Codeine.” insert “Cumyl-PeGaClone.”;
(b) after “Dihydrocodeine.” insert—
Diphenidine.
Ephenidine.
;
(c) after “Methcathinone” insert “Methoxyphenidine.”.
(4) In Part 3 (which specifies the drugs which are subject to control as Class C drugs) in paragraph 1(a) after “Pyrovalerone.” insert “Remimazolam.”.
Propose a change